Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

Ex-FDA chief Gottlieb’s quick move to pharma raises eyebrows

Will join Pfizer board

- PMLiVE

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Could add $1bn to revenues, say analysts

- PMLiVE

Sanofi/Regeneron’s Dupixent successor underwhelms in phase 2

Success against placebo, but fails to outperform Dupixent

Sanofi reception

Sanofi sheds jobs in R&D restructuring

New R&D chief diverting funds to new therapy areas

- PMLiVE

Merck says it has plenty in the pipe beyond Keytruda

It has the firepower, but is Merck seeking a big deal?

- PMLiVE

Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst

Move cuts pipeline depth, says GlobalData

- PMLiVE

Keytruda begins pursuit of rivals in small cell lung cancer

Set for competition with Opdivo

- PMLiVE

Sanofi taps Google’s expertise for digital transformation

Pharma giant embraces AI with new partnership

Novartis day

Novartis close to US bribery settlement

Company faces huge damages pay out

- PMLiVE

Hudson named Brandicourt’s successor as Sanofi’s CEO

Sanofi shaking off patent expiries

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

- PMLiVE

Research charity LifeArc cashes $1.2bn royalty from Keytruda

UK medical research charity pledges to expand its work

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links